The Melbourne Symphony Orchestra Selects Brightcove to Power New Digital Platform
17.5.2021 02:00:00 EEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced that the Melbourne Symphony Orchestra (MSO) is using Brightcove to power its new digital platform MSO.LIVE to cast the Orchestra’s 2021 season in Australia and around the world.
“Brightcove’s technology delivers a polished interface with exceptional quality of video and audio across multiple devices, to ensure we can deliver easily accessible, world-class digital experiences to all audiences,” said Sophie Galaise, Managing Director of the Melbourne Symphony Orchestra.
The MSO is a world-class orchestra with global credibility in providing enriching music experiences to audiences. MSO.LIVE offers 24-hour entertainment on-demand, live, and pre-recorded, delivering accessible and premium content as an alternative to traditional, in-person orchestral experiences. The MSO.LIVE experience is accessible, offering MSO concerts, family programming, and special events and performances from around the world.
A key driver for implementing Brightcove’s online video platform is to make performance experiences easily accessible and affordable to a wider audience, including those who are unable to attend in-person concerts.
The MSO’s main focus is to optimise its content delivery experience to retain existing orchestral music fans and attract new audiences from around the world to the MSO.LIVE platform. New performances are released monthly, and MSO.LIVE members are able to view content across devices and connected TVs.
Using Brightcove, MSO.LIVE demonstrates innovation within the Australian arts community by offering a contemporary content library personalised to audience preferences. “Among other criteria, we selected Brightcove as their local team of experts had the capabilities to integrate customer data with our CRM system,” said Ms. Galaise.
MSO.LIVE offers a range of traditional and contemporary content from both the MSO and other world-class orchestras from around the world, such as the Berliner Philharmoniker and Royal Concertgebouw Orchestra.
MSO.LIVE is priced at $15 per month or $144 per year for an annual subscription, or audiences can subscribe to a one-month pass or pay-per-view access. MSO.LIVE also offers a selection of free content, including programs for kids, audio, and more. View MSO.LIVE here.
“Our partnership with the Melbourne Symphony Orchestra demonstrates the power that video provides to the entertainment and music industry,” said Jennifer Smith, Chief Marketing Officer, Brightcove. “Brands in the Arts and Entertainment sector are embracing the hybrid model to allow them to grow their audiences to engage both in-person and online viewers. 2020 drove the urgency to pivot to new digital video experiences, and businesses are now embracing this as a long-term growth strategy. MSO.LIVE takes the orchestral experience to the next level and cements the MSO as a leader when it comes to the future of live performances,” said Smith.
As part of a longer-term strategy, the introduction of MSO.LIVE will help demonstrate Australia’s unique culture and celebrate the diverse talents of its local artists with the rest of the world.
About Melbourne Symphony Orchestra
Each year, the MSO engages with more than 5 million people through live concerts, TV, radio and online broadcasts, international and regional tours, recordings and education programs.
The MSO is a vital presence, both onstage and in the community, in cultivating classical music in Australia. Internationally acclaimed, the Orchestra nurtures strong cultural partnerships throughout South-East Asia. The MSO is the only Australian orchestra partnered with UNITEL, the world’s leading distributor of classical music programs for film, television and video.
The MSO regularly attracts great artists from around the globe, including Anne-Sophie Mutter, Lang Lang, Renée Fleming and Nick Cave, while bringing Melbourne’s finest musicians to the world through tours to China, Indonesia, Europe and the United States.
The nation’s first professional orchestra, the Melbourne Symphony Orchestra has been the sound of the city of Melbourne since 1906. www.mso.com.au.
About Brightcove Inc.
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organisations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business™
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210516005011/en/
Contact information
Brightcove Press
Meredith Duhaime
Senior Public Relations Manager
Brightcove | (603) 785-8518
mduhaime@brightcove.com
Livia Budisetio
Account Executive
LEWIS Global Communications | (61) 411 208 431
brightcoveANZ@teamlewis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom